Aims Diabetes Mellitus predisposes patients to invasive fungal infections. There has been a recent surge of Mucormycosis with COVID 19 infection particularly in patients with diabetes. This study aims to study the clinical spectrum of CAM (COVID -associated Mucormycosis) with diabetes and subsequent outcomes. Material and methods This was a descriptive study conducted at a single COVID Care Centre in India in patients with COVID Associated Mucormycosis from April 12, 2021 to May 31, 2021. Results Among 953 hospitalized patients with COVID 19 infection, 32 patients had CAM with an incidence of 3.36%. In patients with CAM, 87.5% had Diabetes Mellitus as the most common co-morbidity. The majority of the patients had poor glycemic control with a mean HbA1c of 9.06%. Out of the total study population, 93% had prior exposure to high dose corticosteroids. During the study period, 12.5% patients of CAM did not survive. Conclusion Mucormycosis is an angioinvasive fungal infection with high mortality. The disease has surged in COVID 19 pandemic due to uncontrolled diabetes and improper corticosteroid use.

No abstract

No abstract

A quantitative model for pore growth during initial-stage sintering is proposed. During initial-stage sintering, neck formation leads to surface rounding of the pores, thereby causing a decrease in the surface area of the system. The decrease in surface area, without a concomitant decrease in pore volume, leads to a spurious increase in pore size, as calculated by the gas adsorption technique. Geometrical calculations predict a final pore size that is a function of the initial (green) density of the compact. For the 62% dense compacts of the present study, the model predicts a factor of 1.28 increase in pore size, compared to the factor of 1.27, which is experimentally observed. Interestingly, a common, constant factor of 1.27 can also be observed in pore growth data reported by a number of other researchers.

No abstract